GSK’s lung cancer therapy gains EMA PRIME designation
GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) designation from the European Medicines Agency (EMA) for…
Respiratory
-
-
Trevi’s chronic cough trial in IPF subjects continues without sample size change
Trevi Therapeutics has announced that its Phase IIb CORAL trial of Haduvio in treating idiopathic pulmonary fibrosis (IPF) subjects with…
-
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial
US-based biotechnology company Enanta Pharmaceuticals has reported positive topline outcomes from its randomised Phase II trial of zelicapavir, a potential…
-
MSD’s trial of drug for pulmonary arterial hypertension meets primary endpoint
US-based pharmaceutical company MSD has reported that the Phase III ZENITH trial of WINREVAIR (sotatercept-csrk) for pulmonary arterial hypertension (PAH)…
-
ArkBio concludes dosing for RSV prevention trial in infants
Shanghai Ark Biopharmaceutical (ArkBio) has concluded enrolment and dosing for a Phase I trial of fully human monoclonal antibody, AK0610,…
-
Endeavor doses first subject in Phase IIb trial of ENV-101 for IPF treatment
Endeavor BioMedicines has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial in Australia, assessing the efficacy and…
-
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration,…
-
Paratek’s antibiotic succeeds in Phase IIb lung disease trial
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in…
-
Qnovia set to trial smoking cessation inhaler in the US
Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX…
-
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
